Table 2 Comparison of clinical characteristics of HGSOC patients in relation to platinum-sensitivity

Age at diagnosis (yrs)

62.6 ± 10.1

60.5 ± 8.6

62.8 ± 10.2

0.8

BMI (Kg/m2)

23.3 ± 2.8

25.2 ± 2.1

22.2 ± 2.6

0.2

Previous cancer

1 (5.9%)

0 (0%)

1 (20%)

0.4

 Breast cancer

0 (0%)

0 (0%)

1 (100%)

-

 Gastrointestinal Stromal Tumors

1 (100%)

0 (0%)

0 (0%)

-

 Thyroid cancer

0 (0%)

0 (0%)

0 (0%)

-

Comorbidity

 Hypertension

4 (23.5%)

1 (16.7%)

2 (40%)

0.6

 Hypercholesterolemia

2 (11.8%)

1 (16.7%)

1 (20%)

0.9

 Hypertrigliceridemia

1 (5.9%)

1 (16.7%)

0 (0%)

0.5

 Heart disease

1 (5.9%)

0 (0%)

0 (0%)

0.7

 Depression

1 (5.9%)

0 (0%)

0 (0%)

0.7

 Diabetes mellitus

0 (0%)

1 (16.7%)

1 (20%)

0.2

 BRCA 1 mut

5 (29.4%)

0 (0%)

0 (0%)

0.1

 BRCA 2 mut

5 (29.4%)

0 (0%)

0 (0%)

0.1

 BRCA wt

7 (41.2%)

6 (100%)

5 (100%)

< 0.01

Surgery

 PDS

7 (41.2%)

1 (16.7%)

0 (0%)

0.1

 IDS

7 (41.2%)

1 (16.7%)

3 (60%)

0.3

TR

2 (11.8%)

0 (0%)

2 (40%)

0.1

 0^a

15 (88.2%)

6 (100%)

3 (60%)

0.1

 ≤ 1 cm

2 (11.8%)

0 (0%)

1 (20%)

-

 > 1 cm

0 (0%)

0 (0%)

1 (20%)

-

Fist line chemotherapy

 Carboplatin Taxol

8 (47%)

3 (50%)

3 (60%)

0.9

 Carboplatin Taxol Bevacizumab

7 (41.2%)

1 (16.7%)

2 (40%)

0.5

 Others

2 (11.8%)

2 (33.3%)

0 (0%)

0.2

Maintenance therapy

14 (82.3%)

5 (83.3%)

1 (20%)

< 0.05

 Niraparib

2 (14.3%)

0 (0%)

0 (0%)

0.6

 Bevacizumab

4 (28.6%)

2 (40%)

0 (0%)

0.7

 Olaparib

4 (28.6%)

1 (20%)

0 (0%)

0.8

 Bevacizumab+Olaparib

1 (7.1%)

0 (0%)

1 (100%)

< 0.01

 Others

3 (21.4%)

2 (40%)

0 (0%)

0.6

FIGO stage

 IIIC

14 (82.3%)

4 (66.6%)

2 (40%)

0.2

 IVA

1 (5.9%)

1 (16.7%)

1 (20%)

0.6

 IVB

2 (11.8%)

1 (16.7%)

2 (40%)

0.3

Prognosis

 Recurrence

14 (82.3%)

6 (100%)

4 (80%)

0.5

 PFI (months)

18.5 ± 10.9

5 ± 0

3.2 ± 1.3

< 0.0001

 DFS (months)

30.3 ± 15.6

15.7 ± 8.2

9.5 ± 3.5

< 0.05

 OS (months)

44.9 ± 17.6

22.5 ± 9.2

14.2± 3.6

< 0.01